Evidence map›Paper›PMID 40438003›Full record

ArticleHistology and histopathology2026

HMMR inhibition by 4-methylumbelliferone is effective in preclinical hepatocellular carcinoma models.

Ying Zhu, Ge Sang Wang Dui, Suo Lang Bai Ma, Ci Yang, Wen Xu, Jianguo Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying Zhu *Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China.
Ge Sang Wang Dui *Medical Department, Chayu County People's Hospital, Chayu, Xizang, China.
Suo Lang Bai MaMedical Department, Chayu County People's Hospital, Chayu, Xizang, China.
Ci YangMedical Department, Chayu County People's Hospital, Chayu, Xizang, China.
Wen XuDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China. xuwen@smu.edu.cn.
Jianguo XuDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China. xujianguo1@smu.edu.cn.

Funding

Nyingchi City Science and Technology central plan to guide local projects ZYYDDF2024-04
6 · The paper itself

Abstract

The poor prognosis of hepatocellular carcinoma (HCC), especially in advanced stages, underscores the need for new therapeutic strategies. In this study, we show that hyaluronan-mediated motility receptor (HMMR) is highly expressed in HCC tumors compared with normal liver tissues. Knockdown of HMMR using siRNA significantly reduced cell proliferation and migration in both parental and doxorubicin-resistant HCC cell lines without inducing apoptosis. Similarly, treatment with 4-Methylumbelliferone (4-MU), a pharmacological HMMR inhibitor, led to dose-dependent decreases in proliferation and migration

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularHymecromoneLiver NeoplasmsAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDrug Resistance, NeoplasmHep G2 CellsHumansMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsHymecromone

Identifiers

PMID40438003

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.